AbbVie has acquired global rights to the lead pipeline asset of Ichnos Glenmark Innovation (IGI), the cancer and autoimmune disease candidate ISB 2001, through an exclusive licensing agreement that ...

David Mulligan, PhD, previews the FDA's ODAC meeting discussing the application of belantamab mafodotin-based combinations for the treatment of multiple myeloma.

Tony Newberne is a high-risk multiple myeloma survivor. He is also a CPT, dietary manager, and patient advocate for several ...

Patients with (RRMM) and extramedullary disease (EMD) represent a particularly high-risk population with historically poor outcomes. In a new phase 2 analysis presented at the European Hematology ...

The FDA is reevaluating GlaxoSmithKline’s blood cancer drug Blenrep following mixed results from two phase 3 trials and mounting concerns about eye-related side effects and dosing. The agency is ...

Panelists discuss the growing promise of GPRC5D-targeted therapy in relapsed/refractory multiple myeloma, highlighting MonumenTAL-1 trial data showing encouraging responses in heavily pretreated ...